What is readthrough?
A biotech intelligence feed built only from primary sources. It reads FDA, SEC, and ClinicalTrials.gov records as they update, writes an original summary of each development, and links every claim to the document it came from. You watch companies and drugs and get the stories that matter by web, email digest, RSS, Slack, or Teams.
Where does the information come from?
SEC EDGAR filings (8-K, 10-K, 10-Q, S-1, 424B, Form D, 13D/G, DEF 14A), FDA sources (Drugs@FDA approvals, enforcement and recalls, drug shortages, FDA press releases, and the What's New feeds for drugs and biologics), and ClinicalTrials.gov. No news sites, trade press, or wire copy.
What does readthrough not cover?
Today: company press releases and IR pages (unless the news is also in an SEC filing, an FDA record, or a trial registry), the EMA and other non-U.S. regulators, conference abstracts, journal publications, and patents. The coverage section above lists what is monitored and how often.
How are stories written and checked?
An AI language model writes each story from the source documents with a citation on every factual sentence, and a second automated pass checks each claim against those documents. A sentence the check cannot confirm is removed and the story says so; a story that cannot be supported as written is published as a short notice linking to the record instead. Stories publish without a person reviewing them first, and corrections are shown on the story when a published one is wrong.
How current is the feed?
New filings are stored within minutes of appearing on EDGAR, and stories usually publish within the hour. FDA and ClinicalTrials.gov sources are read on their own publication schedules, from every thirty minutes to daily.
How far back does the data go?
To June 27, 2026, ninety days before launch, and forward from there. The feed is about what is happening now; older history is available in the linked source documents.
Which drugs does it know about?
Every drug with an active FDA application (NDA or BLA), with its brand names, generic name, and first approval date from Drugs@FDA, plus every investigational product in trials led by a covered company, under the sponsor codes and nonproprietary names the registry uses. A drug's page shows who develops it, its aliases, and every story that names it.
Is readthrough investment advice?
No. Stories are summaries of public records. They contain no ratings, price targets, or recommendations, and nothing on the site is a suggestion to buy or sell any security.
How much does it cost?
$29 per seat per month, or $300 per seat per year. Every plan starts with a 14-day free trial with all features and no card required. Companies that want everyone on their email domain to sign in without seat counting can request enterprise access at app.readthrough.bio/enterprise.
Can I get stories into Slack or Teams?
Yes. Workspace admins add a Slack incoming webhook or a Teams Workflows webhook under Settings, per watch list or for the whole workspace, and new stories post as they publish. Private RSS feeds and a daily email digest are also included.
Is there an API?
Yes. A read API returns stories with their citations, company and drug profiles, search, and your watch lists as JSON, with per-workspace keys created in Settings. An MCP server gives AI assistants the same access with the same key. The reference is in the app once you sign in.